Improving detection of arrhythmia drug-drug interactions in pharmacovigilance data through the implementation of similarity-based modeling

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Vilar, Santiago ^a,b   Lorberbaum, Tal ^a   Hripcsak, George ^a,b   Tatonetti, Nicholas P ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Observational Health Data Sciences and Informatics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DILTIAZEM; DISOPYRAMIDE; FLUCONAZOLE; GATIFLOXACIN; IMIPRAMINE; METHADONE; RANOLAZINE;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG INFORMATION; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; HEART ARRHYTHMIA; HUMAN; INFORMATION PROCESSING; MATHEMATICAL COMPUTING; PATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; QUALITY OF LIFE; ALGORITHM; ARRHYTHMIAS, CARDIAC; DRUG INTERACTION;

ALGORITHMS; ARRHYTHMIAS, CARDIAC; DRUG INTERACTIONS; HUMANS; PHARMACOVIGILANCE;

EID: 84935141074     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129974     Document Type: Article

References (34)

1. Tatonetti NP, Fernald GH, Altman RB. A novel signal detection algorithm for identifying hidden drugdrug interactions in adverse event reports. J Am Med Inform Assoc. 2012; 19(1):79-85. doi: 10.1136/ amiajnl-2011-000214 PMID: 21676938
2. Pirmohamed M. Ml O: Drug Interactions of Clinical Importance. London: Chapman & Hall; 1998.
3. Percha B, Altman RB. Informatics confronts drug-drug interactions. Trends Pharmacol Sci. 2013; 34(3):178-84. doi: 10.1016/j.tips.2013.01.006 PMID: 23414686
4. Rice PJ, Perry RJ, Afzal Z, Stockley IH. Antibacterial prescribing and warfarin: a review. Br Dent J. 2003; 194(8):411-5. PMID: 12778089
5. Krishna G, Ma L, Prasad P, Moton A, Martinho M, O'Mara E. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol. 2012; 8(1): 1-10. doi: 10.1517/17425255.2012.639360 PMID: 22176629
6. Korhonen LE, Rahnasto M, Mahonen NJ, Wittekindt C, Poso A, Juvonen RO, et al. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005; 48(11):3808-15. PMID: 15916432
7. Rahnasto M, Raunio H, Poso A, Wittekindt C, Juvonen RO. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J Med Chem. 2005; 48(2):440-9. PMID: 15658857
8. Yap CW, Chen YZ. Prediction of cytochrome p450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines. J Chem Inf Model. 2005; 45(4):982-92. PMID: 16045292
9. Afzelius L, Zamora I, Ridderstrom M, Andersson TB, Karlen A, Masimirembwa CM. Competitive CYP2C9 inhibitors: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol. 2001; 59(4):909-19. PMID: 11259637
10. De Rienzo F, Fanelli F, Menziani MC, De Benedetti PG. Theoretical investigation of substrate specificity for cytochromes p450 IA2, p450 IID6 and p450 IIIA4. J Comput Aided Mol Des. 2000; 14(1):93-116. PMID: 10702928
11. Vilar S, Harpaz R, Uriarte E, Santana L, Rabadan R, Friedman C. Drug-drug interaction through molecular structure similarity analysis. J Am Med Inform Assoc. 2012; 19(6):1066-74. doi: 10.1136/amiajnl-2012-000935 PMID: 22647690
12. Vilar S, Uriarte E, Santana L, Tatonetti NP, Friedman C. Detection of drug-drug interactions by modeling interaction profile fingerprints. PLOS ONE. 2013; 8(3):e58321. doi: 10.1371/journal.pone.0058321 PMID: 23520498
13. Gottlieb A, Stein GY, Oron Y, Ruppin E, Sharan R. INDI: a computational framework for inferring drug interactions and their associated recommendations. Mol Syst Biol. 2012; 8:592. doi: 10.1038/msb. 2012.26 PMID: 22806140
14. Tari L, Anwar S, Liang S, Cai J, Baral C. Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics. 2010; 26(18):i547-i53. doi: 10. 1093/bioinformatics/btq382 PMID: 20823320
15. Percha B, Garten Y, Altman RB. Discovery and explanation of drug-drug interactions via text mining. Pac Symp Biocomput. 2012 2012:410-21.
16. FDA U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). Available: http://www.fda.gov/cder/aers/default.htm. Accessed 01 Apr 2014.
17. Harpaz R, Chase HS, Friedman C. Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics. 2010; 11(Suppl 9):S7. doi: 10.1186/1471-2105-11-S9-S7 PMID: 21044365
18. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-Driven Prediction of Drug Effects and Interactions. Sci Transl Med. 2012; 4(125): 125ra31. doi: 10.1126/scitranslmed.3003377 PMID: 22422992
19. Vilar S, Harpaz R, Chase HS, Costanzi S, Rabadan R, Friedman C. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J Am Med Inf Assoc. 2011; 18:I73-I80. doi: 10.1136/amiajnl-2011-000417 PMID: 21946238
20. Vilar S, Harpaz R, Santana L, Uriarte E, Friedman C. Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS One. 2012; 7(7):e41471. doi: 10.1371/journal.pone.0041471 PMID: 22911794
21. DrugBank database, version 3.0. Accessed: http://www.drugbank.ca. Accessed 15 Apr 2011.
22. Olvey EL, Clauschee S, Malone DC. Comparison of Critical Drug-Drug Interaction Listings: The Department of Veterans Affairs Medical System and Standard Reference Compendia. Clin Pharmacol Ther. 2010; 87(1):48-51. doi: 10.1038/clpt.2009.198 PMID: 19890252
23. Durant JL, Leland BA, Henry DR, Nourse JG. Reoptimization of MDL keys for use in drug discovery. J Chem Inf Comput Sci. 2002; 42(6):1273-80. PMID: 12444722
24. Schrödinger package, version 9.2, Schrödinger, LLC, New York, USA, 2011. Available: http://www. schrodinger.com (Accessed 15 Oct 2013).
25. Vilar S, Uriarte E, Santana L, Friedman C, Tatonetti NP. State of the art and development of a drugdrug interaction large scale predictor based on 3D pharmacophoric similarity. Curr Drug Metab. 2014; 15(5):490-501. PMID: 25431152
26. SIDER Side Effect Resource. Accessed: http://sideeffects.embl.de. Accessed 01 May 2013.
27. WHO Collaborating Centre for Drug Statistics Methodology (WHOCC). Available: http://www.whocc. no. Accessed 01 Jun 2014.
28. Vilar S, Uriarte E, Santana L, Lorberbaum T, Hripcsak G, Friedman C, et al. Similarity-based modeling in large-scale prediction of drug-drug interactions. Nat Protoc. 2014; 9(9):2147-2163. doi: 10.1038/ nprot.2014.151 PMID: 25122524
29. Drugdex System (Micromedex Healthcare Series). Greenwood Village, CO: Thomson Reuters (Healthcare) Inc., 2011. Available: http://www.micromedexsolutions.com. Accessed 01 Mar 2014.
30. Drug Information Online, Drugs.com database. Available: http://www.drugs.com (Accessed 01 Mar 2014).
31. The Truven MarketScan Commercial Claims and Encounters (CCAE). Available: http://www. truvenhealth.com. Accessed 01 Jun 2014.
32. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003; 23(7):881-908. PMID: 12885102
33. Cheng F, Zhao Z. Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. J Am Med Inform Assoc. 2014; 21(e2):e278-86. doi: 10.1136/amiajnl-2013-002512 PMID: 24644270
34. Vilar S, Ryan PB, Madigan D, Stang PE, Schuemie MJ, Friedman C, et al. Similarity-based modeling applied to signal detection in pharmacovigilance. CPT Pharmacometrics Syst Pharmacol. 2014; 3: e137. doi: 10.1038/psp.2014.35 PMID: 25250527